Study Design and Rationale for the TETON Phase 3 Clinical Trials of Inhaled Treprostinil in the Treatment of Idiopathic Pulmonary Fibrosis
S. Nathan (Falls Church, United States), J. Behr (Munich, Germany), V. Cottin (Lyon, France), L. Lancaster (Nashville, United States), P. Smith (RTP, United States), C. Deng (RTP, United States), N. Pearce (RTP, United States), H. Bell (RTP, United States), L. Peterson (RTP, United States), K. Flaherty (Ann Arbor, United States)
Source: International Congress 2022 – Promising new approaches in idiopathic interstitial pneumonias
 
Rating: 
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
S. Nathan (Falls Church, United States), J. Behr (Munich, Germany), V. Cottin (Lyon, France), L. Lancaster (Nashville, United States), P. Smith (RTP, United States), C. Deng (RTP, United States), N. Pearce (RTP, United States), H. Bell (RTP, United States), L. Peterson (RTP, United States), K. Flaherty (Ann Arbor, United States). Study Design and Rationale for the TETON Phase 3 Clinical Trials of Inhaled Treprostinil in the Treatment of Idiopathic Pulmonary Fibrosis. 1934
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
|
|